We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Groundbreaking Blood Test Detects Earliest Signs of Pancreatic Cancer Before Symptoms Appear

By LabMedica International staff writers
Posted on 24 Dec 2024
Print article
Image: The groundbreaking genomics method has the potential to uncover insights previously missed (Photo courtesy of Breakthrough Genomics)
Image: The groundbreaking genomics method has the potential to uncover insights previously missed (Photo courtesy of Breakthrough Genomics)

Pancreatic cancer often remains undetected until it has progressed beyond the pancreas, typically because it presents no noticeable symptoms in its early stages. Consequently, pancreatic cancer has one of the highest mortality rates, with survival rates largely unchanged despite advancements in the treatment of other cancers. Early detection is vital for this type of cancer, as most cases are diagnosed at an advanced stage, limiting treatment options. While new treatment options for pancreatic cancer have emerged, their success still relies heavily on the ability to detect the disease early. Now, a groundbreaking blood test can identify pancreatic cancer at its earliest stages, even before symptoms develop. This test works by detecting tumor-derived cell-free DNA that cancer cells release into the bloodstream. These DNA fragments carry distinct signatures unique to pancreatic cancer, allowing for their identification even in very low concentrations.

The BT-Reveal early pancreatic cancer test, developed by Breakthrough Genomics (Irvine, CA, USA), is the first blood-based test of its kind, offering at-risk individuals the ability to detect pancreatic cancer early without the high costs and side effects associated with MRIs and other diagnostic methods. Powered by patented DNA methylation technology, the test detects the earliest signs of pancreatic cancer in circulating cell-free DNA, often before symptoms manifest. DNA methylation involves the switching on and off of DNA molecules to regulate cellular functions. The test identifies abnormal DNA methylation patterns in the blood, which serve as early indicators of pancreatic cancer. On a molecular level, the test analyzes 59 specific DNA methylation regions (biomarkers) that have been strongly associated with pancreatic cancer.

BT-Reveal is a non-invasive, life-saving test that successfully detects 83% of pancreatic cancers, including those in the early Stage 1 and 2. This blood test offers a convenient biochemical alternative to traditional diagnostic methods, helping to screen for pancreatic cancer without the side effects or logistical challenges associated with imaging techniques. It provides an effective and less invasive way to identify pancreatic cancer, especially in clinical settings where quick and reliable detection is crucial. The test has received the FDA's Breakthrough Device Designation and is currently available for high-risk patients through Breakthrough Genomics.

Related Links:
Breakthrough Genomics

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit
New
Hematology Analyzer
BH-6180

Print article

Channels

Hematology

view channel
Image: The new test could improve specialist transplant and transfusion practice as well as blood banking (Photo courtesy of NHS Blood and Transplant)

New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape

The release of oxygen by red blood cells is a critical process for oxygenating the body's tissues, including organs and muscles, particularly in individuals receiving large blood transfusions.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The iFAST reader scans 5000 individual bacteria with each sample analyzed in less than a minute (Photo courtesy of iFAST)

High-Throughput AST System Uses Microchip Technology to Rapidly Analyze Bacterial Samples

Bacteria are becoming increasingly resistant to antibiotics, with resistance levels ranging from 20% to 98%, and these levels are unpredictable. Currently, antimicrobial susceptibility testing (AST) takes... Read more

Pathology

view channel
Image: These images show the high resolution achieved with the new microscopy technique (Photo courtesy of Cao, R. et al. Science Advance, 2024. Caltech)

New Microscopy Technique Enables Rapid Tumor Analysis by Surgeons in OR

The current standard method for quickly sampling and imaging tissue during surgery involves taking a biopsy, freezing the sample, staining it to enhance visibility, and slicing it into thin sections that... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.